The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Zanzalintinib (zanza) + nivolumab (nivo) ± relatlimab (rela) in patients (pts) with previously untreated clear cell renal cell carcinoma (ccRCC): Results from an expansion cohort of the phase 1b STELLAR-002 study.
 
Jad Chahoud
Consulting or Advisory Role - AVEO; DAVA Pharmaceuticals; Eisai; Exelixis; Merck; Pfizer
Research Funding - AB Science (Inst); Allogene Therapeutics (Inst); Exelixis (Inst); Merck (Inst); Pfizer (Inst); Xilio Therapeutics (Inst)
 
Bradley McGregor
Consulting or Advisory Role - Arcus Biosciences; Astellas Pharma; AVEO; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; Exelixis; Genmab; Gilead Sciences; Hexagon; Loxo/Lilly; Pfizer; Seattle Genetics/Astellas
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Pfizer/EMD Serono (Inst); Seattle Genetics/Astellas (Inst)
 
Oscar Reig Torras
Stock and Other Ownership Interests - Bristol Myers Squibb; Merck; Pfizer
Honoraria - Astellas Pharma; BMS; Ipsen; Merck; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Pfizer; Sanofi
Travel, Accommodations, Expenses - Ipsen; Merck
 
Pedro Barata
Stock and Other Ownership Interests - Luminate Medical
Honoraria - UroToday
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; AVEO; Bayer; BMS; Caris Life Sciences; Dendreon (Inst); Eisai; EMD Serono; Exelixis; Ipson; Merck; Novartis; Pfizer
Speakers' Bureau - AstraZeneca; Bayer (Inst); Caris Life Sciences (Inst); Merck; Pfizer/Astellas (Inst)
Research Funding - AVEO (Inst); Blue Earth Diagnostics (Inst); Exelixis; Merck (Inst); Pfizer (Inst)
 
Jonathan Chatzkel
Research Funding - Aveo (Inst); Exelixis (Inst); Genentech (Inst); Merck (Inst)
 
Simon Fu
Consulting or Advisory Role - MSD Oncology
Travel, Accommodations, Expenses - Roche; Roche; Roche/Genentech
 
Daniel Castellano Gauna
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi
Research Funding - Janssen Oncology (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Bristol-Myers Squibb; Novartis; Pfizer; Roche
 
Pablo Maroto-Rey
Consulting or Advisory Role - Astellas Pharma; Bayer; BMS; Ipsen; Janssen; Merck/Pfizer; MSD
Expert Testimony - Amgen
Travel, Accommodations, Expenses - Bayer; Ipsen; Merck/Pfizer
 
Julia Martinez Perez
No Relationships to Disclose
 
Philippe Barthelemy
Honoraria - Astellas Pharma; AstraZeneca; Bayer; BMS; Gilead Sciences; IPSEN; Janssen-Cilag; Merck KGaA; MSD; Novartis; Pfizer
Consulting or Advisory Role - AAA/Endocyte/Novartis; Amgen; AstraZeneca; Bayer; BMS; Eisai; Gilead Sciences; ipsen; Janssen-Cilag; Merck KGaA; MSD Oncology; Pfizer
Research Funding - IPSEN (Inst)
Travel, Accommodations, Expenses - BMS; IPSEN; Janssen-Cilag; Merck/Pfizer; MSD; Pfizer
 
Joanna Wojcik-Tomaszewska
Research Funding - AVEO; Bristol-Myers Squibb; ICON Clinical Research; Lilly; MSD Oncology; Roche
 
Benjamin Garmezy
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); crispr therapeutics (Inst); Eikon Therapuetics (Inst); Envision Pharma Group (Inst); Exelixis (Inst); Flare Therapeutics (Inst); Genentech (Inst); Harbour BioMed (Inst); IDEAYA Biosciences (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jubilant Therapeutics (Inst); Kineta (Inst); Kinnate Biopharma (Inst); Loxo (Inst); Loxo/Lilly (Inst); MiNK Therapeutics (Inst); Nuvation Bio (Inst); ProfoundBio (Inst); Roche/Genentech (Inst); Takeda (Inst); Teon Therapeutics (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst); Xencor (Inst); Zenshine (Inst); Zenshine (Inst)
(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Adaptimmune (Inst); Adicet Bio (Inst); AIQ Global (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); Exelixis (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Rondo Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Xencor (Inst)
 
Marta González Cordero
Honoraria - Amgen; Astellas Pharma; Bayer; Merck; MSD Oncology
Consulting or Advisory Role - AstraZeneca Spain; MSD Oncology
Travel, Accommodations, Expenses - Bayer; Janssen Oncology; Merck; Roche
 
Mohan Liu
Stock and Other Ownership Interests - Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation
 
Xinyu Wang
No Relationships to Disclose
 
John Russell
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis; GlaxoSmithKline; Haleon
 
Lana Andrianova
Employment - Exelixis; InhibRx (I); InhibRx (I)
Stock and Other Ownership Interests - Exelixis; InhibRx (I)
Consulting or Advisory Role - Exelixis (I)
 
Neil Shah
Honoraria - MJH Life Sciences
Consulting or Advisory Role - Merck Sharp & Dohme Corp.
Research Funding - Aravive (Inst); Exelixis; HiberCell (Inst)
Travel, Accommodations, Expenses - Merck